Abstract

BackgroundOsteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients. OPN contains two integrin-binding sites and a thrombin cleavage domain located in close proximity to each other.MethodsTo study the role of the thrombin cleavage site of OPN, MDA-MB-468 human breast cancer cells were stably transfected with either wildtype OPN (468-OPN), mutant OPN lacking the thrombin cleavage domain (468-ΔTC) or an empty vector (468-CON) and assessed for in vitro and in vivo functional differences in malignant/metastatic behavior.ResultsAll three cell lines were found to equivalently express thrombin, tissue factor, CD44, αvβ5 integrin and β1 integrin. Relative to 468-OPN and 468-CON cells, 468-ΔTC cells expressing OPN with a deleted thrombin cleavage domain demonstrated decreased cell adhesion (p < 0.001), decreased mRNA expression of MCAM, maspin and TRAIL (p < 0.01), and increased uPA expression and activity (p < 0.01) in vitro. Furthermore, injection of 468-ΔTC cells into the mammary fat pad of nude mice resulted in decreased primary tumor latency time (p < 0.01) and increased primary tumor growth and lymph node metastatic burden (p < 0.001) compared to 468-OPN and 468-CON cells.ConclusionsThe results presented here suggest that expression of thrombin-uncleavable OPN imparts an early tumor formation advantage as well as a metastatic advantage for breast cancer cells, possibly due to increased proteolytic activity and decreased adhesion and apoptosis. Clarification of the mechanisms responsible for these observations and the translation of this knowledge into the clinic could ultimately provide new therapeutic opportunities for combating breast cancer.

Highlights

  • Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients

  • OPN has been shown to interact with cell surface receptors [15,19,21,25], secreted proteases [17,24] and growth factor/ receptor pathways (EGFR, Met) [16,18] in order to exert its malignancy-promoting effects

  • We investigated the biochemical and functional relationship between OPN and thrombin during breast cancer metastasis using the 468-CON and 468-OPN human breast cancer cell lines, as well as a third cell line (468-ΔTC) which expresses a mutant OPN lacking the thrombin cleavage domain

Read more

Summary

Introduction

Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients. In breast cancer patients with metastatic disease, elevated levels of baseline OPN in plasma have been linked to poor prognosis [11,12]. OPN has been functionally associated with growth, survival, adhesion, migration, invasion, angiogenesis and metastasis of breast cancer cells [14,15,16,17,18,19,20,21,22,23,24]. OPN has been shown to interact with cell surface receptors (integrins, CD44) [15,19,21,25], secreted proteases (urokinase plasminogen activator, thrombin) [17,24] and growth factor/ receptor pathways (EGFR, Met) [16,18] in order to exert its malignancy-promoting effects

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call